Dissema Pharma SRL
Dissema Pharma reported total assets of 492,965 € at the end of the 2025 financial year (annual accounts filed with the NBB on 22 Jul 2026).
The score of Dissema Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +46 % Total assets -7 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Dissema Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 26,259 € | ||||
| Equity | 293,207 € | ||||
| Cash | 10,630 € | ||||
| EBITDA | 44,319 € | ||||
| Total assets | 492,965 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 Jul 2026
- Year ended 31 Dec 2024filed on 04 Aug 2025
- Year ended 31 Dec 2023filed on 12 Aug 2024
- Year ended 31 Dec 2022filed on 17 Aug 2023
- Year ended 31 Dec 2021filed on 26 Aug 2022
Dissema Pharma's financial analysis
- Solvency59.5%sector median: 60.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Dissema Pharma
Dissema Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0659.809.737
- VAT number
- BE0659809737
- Peppol
- Registered · 0208:0659809737 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 20 Jul 2016
- Registered office
- 1082 Berchem-Sainte-Agathe
- Latest accounts
- 2025 · filed on 22 Jul 2026
- Activity
- Activities of holding companies (NACE 64210)
Dissema Pharma (SRL) has been based in Berchem-Sainte-Agathe since 2016, active in: activities of holding companies. For 2025, it reports a net profit of 26,259 € and equity of 293,207 €; its revenue is not published. Its solvency stands at 59.5%, below the median of its sector (60.1%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Dissema Pharma
Companies in the same business, of comparable size and area, outside its group.
- HP Finance Activities of holding companies Leuven · balance sheet 492,568 €
- Pro-Active Insurance Activities of holding companies Hasselt · balance sheet 491,964 €
- Doron Management BV Activities of holding companies Essen · balance sheet 491,603 €
- DSLV Activities of holding companies Wevelgem · balance sheet 494,802 €
- Maene Immo Activities of holding companies Ichtegem · balance sheet 503,863 €
- Corick Activities of holding companies Izegem · balance sheet 489,921 €
- B-S Invest Activities of holding companies Torhout · balance sheet 488,385 €
- CD Invest Activities of holding companies Woluwe-Saint-Lambert · balance sheet 499,548 €
Frequently asked questions about Dissema Pharma
What is the revenue of Dissema Pharma?
Dissema Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Dissema Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0659809737 for Dissema Pharma, if the company is VAT-registered. Its company number (CBE) is 0659.809.737.
Where is the registered office of Dissema Pharma?
According to the CBE register, the registered office of Dissema Pharma is in 1082 Berchem-Sainte-Agathe.
What is the equity of Dissema Pharma?
At the close of the 2025 financial year, the equity of Dissema Pharma amounts to 293,207 €, a solvency of 59.5% of total assets.
Who manages Dissema Pharma?
The register lists 4 active mandates at Dissema Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Dissema Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →